News & Views
Telix today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2022 (Q4 2022). All figures are in AUD$ unless otherwise…
Read more
Telix is pleased to provide a webcast recording of CEO and MD Dr. Christian Behrenbruch presenting at the J.P. Morgan Healthcare Conference on Wednesday 11 January…
Read more
Telix today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9–12 January) in San Francisco. As part of the Company’s presentation (lodged with this announcement), Telix has…
Read more
Telix today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation…
Read more
Telix today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession…
Read more
News,
Telix today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an…
Read more
Telix today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent…
Read more
Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies London Healthcare Conference in London on Thursday 17 November…
Read more
Telix today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development…
Read more
Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of…
Read more